Track Categories
The track category is the heading under which your abstract will be reviewed and later published in the conference printed matters if accepted. During the submission process, you will be asked to select one track category for your abstract.
Breast Cancer 2026 explores breast cancer as a complex disease arising from uncontrolled growth of cells within breast tissue. It encompasses diverse molecular subtypes, clinical behaviours, and therapeutic responses, making personalized management essential.
Advances scientific understanding and compassionate care to improve outcomes across the breast cancer continuum.
Key Highlights:
1.1 Breast Cancer Biology
1.2 Molecular Subtypes
1.3 Disease Progression
1.4 Personalized Management
1.5 Survivorship Strategies
Breast Cancer 2026 examines tumor ecosystems and the dynamic interactions between cancer cells, immune cells, stromal components, and surrounding tissues. These interactions influence tumor growth, metastasis, and treatment response.
Reveals how the tumor environment shapes disease behaviour and patient-centered therapeutic strategies.
Key Highlights:
2.1 Tumor Microenvironment
2.2 Stromal Interactions
2.3 Cellular Communication
2.4 Metastatic Niches
2.5 Therapeutic Target Discovery
Breast Cancer 2026 highlights immune reprogramming approaches that modify immune responses to recognize and eliminate cancer more effectively. It explores mechanisms that overcome tumor-induced immune suppression.
Combines scientific innovation with compassionate treatment approaches to strengthen anti-cancer immunity.
Key Highlights:
3.1 Immune Checkpoints
3.2 T-Cell Engineering
3.3 Tumor Immune Escape
3.4 Immunotherapeutic Strategies
3.5 Immune Modulation Technologies
Breast Cancer 2026 showcases oncology as a multidisciplinary field encompassing the study, diagnosis, treatment, and prevention of cancer. It integrates diverse expertise to improve patient outcomes through evidence-based care.
Promotes holistic breast cancer management by uniting scientific advances with compassionate clinical practice.
Key Highlights:
4.1 Cancer Biology
4.2 Clinical Oncology Advances
4.3 Precision Medicine
4.4 Integrated Care Models
4.5 Emerging Therapies
Breast Cancer 2026 presents digital histology technologies that utilize advanced imaging and computational tools to analyse tissue specimens. It enhances diagnostic accuracy, accessibility, and workflow efficiency in pathology.
Accelerates breast cancer diagnosis through data-driven technologies that support patient-focused care.
Key Highlights:
5.1 Whole Slide Imaging
5.2 AI-Assisted Histology
5.3 Image Quantification
5.4 Digital Diagnostics
5.5 Computational Pathology
Breast Cancer 2026 explores molecular imaging techniques that visualize biological processes at the cellular and molecular levels within living tissues. It provides critical insights into tumor detection and therapeutic monitoring.
Improves early diagnosis and treatment assessment through precise visualization of disease processes.
Key Highlights:
6.1 PET Imaging
6.2 Targeted Imaging Agents
6.3 Functional Imaging
6.4 Tumor Visualization
6.5 Response Monitoring
Supports effective tumor control while prioritizing patient quality of life and treatment outcomes.
Key Highlights:
7.1 Precision Radiotherapy
7.2 Image-Guided Radiation
7.3 Dose Optimization
7.4 Radiation Toxicity Management
7.5 Advanced Treatment Planning
Breast Cancer 2026 highlights hormone signalling pathways that regulate cellular activities and influence tumor growth. These mechanisms are particularly significant in hormone receptor-positive breast cancers. Enhances personalized treatment approaches by understanding hormone-driven disease mechanisms.
Key Highlights:
8.1 Estrogen Signalling
8.2 Progesterone Pathways
8.3 Endocrine Resistance
8.4 Hormone Receptor Biology
8.5 Targeted Endocrine Therapies
Breast Cancer 2026 addresses the importance of minimal residual disease, referring to small numbers of cancer cells that remain after treatment and may contribute to recurrence. Sensitive detection methods are essential for long-term monitoring.
Supports earlier intervention and improved patient outcomes through precise disease surveillance.
Key Highlights:
9.1 Residual Tumor Detection
9.2 Liquid Biopsy Applications
9.3 Disease Monitoring
9.4 Recurrence Prediction
9.5 Clinical Risk Assessment
Breast Cancer 2026 showcases predictive analytics, which uses statistical models, artificial intelligence, and clinical data to forecast disease behaviour and treatment outcomes. It enables more informed clinical decision-making.
Transforms breast cancer data into actionable insights that support personalized and compassionate care.
Key Highlights:
10.1 Risk Prediction Models
10.2 Treatment Response Forecasting
10.3 AI-Based Analytics
10.4 Outcome Assessment
10.5 Clinical Decision Support
Breast Cancer 2026 emphasizes early detection strategies focused on identifying breast cancer at its earliest and most treatable stages. Timely diagnosis significantly improves survival and treatment success.
Empowers proactive care by combining scientific screening advances with patient-centered intervention.
Key Highlights:
11.1 Screening Technologies
11.2 Mammographic Advances
11.3 Risk-Based Detection
11.4 Community Awareness
11.5 Diagnostic Pathways
Breast Cancer 2026 explores treatment adaptation approaches that involve modifying therapeutic strategies based on disease evolution, patient response, and emerging clinical evidence. It supports more effective individualized care.
Ensures that treatment remains responsive to both scientific findings and patient needs.
Key Highlights:
12.1 Adaptive Therapy Models
12.2 Response-Guided Treatment
12.3 Personalized Care Strategies
12.4 Resistance Management
12.5 Dynamic Clinical Decision-Making
Breast Cancer 2026 examines cellular plasticity and the ability of cells to alter their identity, behaviour, and function in response to environmental signals. This phenomenon contributes to tumor progression and resistance.
Provides insights into cancer adaptability while identifying new opportunities for targeted interventions.
Key Highlights:
13.1 Cell State Transitions
13.2 Tumor Heterogeneity
13.3 Therapy Resistance
13.4 Epithelial-Mesenchymal Transition
13.5 Cellular Reprogramming
Breast Cancer 2026 highlights translational breast cancer research that bridges laboratory discoveries and clinical applications. It accelerates the development of innovative diagnostics and therapies.
Transforms scientific discoveries into meaningful improvements in patient care and outcomes.
Key Highlights:
14.1 Bench-to-Bedside Research
14.2 Clinical Translation
14.3 Novel Therapeutics
14.4 Precision Oncology Applications
14.5 Translational Trial Design
Breast Cancer 2026 showcases the role of genetics in exploring inherited and acquired genetic variations associated with breast cancer development and progression. It is fundamental to risk assessment and precision medicine.
Enhances individualized prevention and treatment strategies through genetic understanding.
Key Highlights:
15.1 Hereditary Breast Cancer
15.2 BRCA Mutations
15.3 Genetic Screening
15.4 Risk Stratification
15.5 Genomic Counselling
Breast Cancer 2026 investigates tumor hypoxia, a condition characterized by reduced oxygen availability within tumor tissues that influences cancer progression and therapeutic resistance. It remains a major factor affecting treatment effectiveness.
Improves understanding of aggressive disease behaviour and opportunities for targeted therapies.
Key Highlights:
16.1 Hypoxic Signalling Pathways
16.2 Treatment Resistance
16.3 Tumor Adaptation Mechanisms
16.4 Hypoxia Biomarkers
16.5 Therapeutic Targeting Strategies
Breast Cancer 2026 presents the growing significance of biomarkers as measurable biological indicators used for diagnosis, prognosis, and therapeutic monitoring. They provide critical information for precision oncology.
Supports individualized patient management through accurate and evidence-based decision-making.
Key Highlights:
17.1 Diagnostic Biomarkers
17.2 Prognostic Indicators
17.3 Predictive Markers
17.4 Therapeutic Monitoring
17.5 Biomarker Validation
Breast Cancer 2026 explores chemotherapy as a cornerstone treatment that uses cytotoxic drugs to eliminate cancer cells and reduce tumor burden across multiple disease stages.
Enhances treatment effectiveness while advancing strategies to improve patient experiences and outcomes.
Key Highlights:
18.1 Systemic Therapy Approaches
18.2 Combination Regimens
18.3 Drug Resistance Mechanisms
18.4 Toxicity Management
18.5 Personalized Chemotherapy
Breast Cancer 2026 examines the mammary tumor axis, encompassing the biological networks and signaling pathways that drive breast tumor initiation, growth, and progression. Understanding these pathways is critical for therapeutic development.
Decodes complex tumor biology to identify innovative and patient-focused treatment opportunities.
Key Highlights:
19.1 Tumor Signalling Networks
19.2 Growth Factor Pathways
19.3 Cellular Crosstalk
19.4 Disease Progression Mechanisms
19.5 Therapeutic Targets
Breast Cancer 2026 highlights lymphatic dissemination as a key mechanism through which cancer cells spread via lymphatic vessels to regional lymph nodes and distant sites. It is a critical step in breast cancer metastasis.
Strengthens understanding of disease spread while supporting earlier intervention and improved outcomes.
Key Highlights:
20.1 Lymphatic Biology
20.2 Metastatic Pathways
20.3 Sentinel Node Assessment
20.4 Tumor Cell Migration
20.5 Prognostic Implications
Breast Cancer 2026 explores tissue renewal dynamics and the mechanisms responsible for tissue maintenance, regeneration, and repair. Tissue renewal processes influence both normal breast biology and cancer development.
Links regenerative science with compassionate care to improve recovery and long-term health.
Key Highlights:
21.1 Stem Cell Dynamics
21.2 Tissue Regeneration
21.3 Cellular Turnover
21.4 Repair Mechanisms
21.5 Regenerative Biomarkers
Breast Cancer 2026 showcases case reports that provide detailed analyses of unique clinical presentations, diagnostic challenges, treatment responses, and rare disease manifestations. They contribute valuable real-world evidence to medical practice. Transforms individual patient experiences into shared knowledge that advances both science and compassionate care.
Key Highlights:
22.1 Rare Clinical Presentations
22.2 Diagnostic Challenges
22.3 Treatment Outcomes
22.4 Multidisciplinary Management
22.5 Evidence-Based Learning